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as a tool to monitor activity of the mammalian
WNT/planar cell polarity pathway
Markéta Kaucká1,8†, Julian Petersen2†, Pavlína Janovská1, Tomasz Radaszkiewicz1, Lucie Smyčková1,
Avais M Daulat3,4,5,6, Jean-Paul Borg3,4,5,6, Gunnar Schulte1,2* and Vitezslav Bryja1,7*Abstract
Background: The WNT/planar-cell-polarity (PCP) pathway is a key regulator of cell polarity and directional cell
movements. Core PCP proteins such as Van Gogh-like2 (VANGL2) are evolutionarily highly conserved; however,
the mammalian PCP machinery is still poorly understood mainly due to lack of suitable models and quantitative
methodology. WNT/PCP has been implicated in many human diseases with the most distinguished positive role in
the metastatic process, which accounts for more than 90% of cancer related deaths, and presents therefore an
attractive target for pharmacological interventions. However, cellular assays for the assessment of PCP signaling,
which would allow a more detailed mechanistic analysis of PCP function and possibly also high throughput
screening for chemical compounds targeting mammalian PCP signaling, are still missing.
Results: Here we describe a mammalian cell culture model, which correlates B lymphocyte migration of patient-derived
MEC1 cells and asymmetric localization of fluorescently-tagged VANGL2. We show by live cell imaging that PCP proteins
are polarized in MEC1 cells and that VANGL2 polarization is controlled by the same mechanism as in tissues i.e. it is
dependent on casein kinase 1 activity. In addition, destruction of the actin cytoskeleton leads to migratory arrest and cell
rounding while VANGL2-EGFP remains polarized suggesting that active PCP signaling visualized by polarized distribution
of VANGL2 is a cause for and not a consequence of the asymmetric shape of a migrating cell.
Conclusions: The presented imaging-based methodology allows overcoming limitations of earlier approaches to
study the mammalian WNT/PCP pathway, which required in vivo models and analysis of complex tissues. Our system
investigating PCP-like signaling on a single-cell level thus opens new possibilities for screening of compounds, which
control asymmetric distribution of proteins in the PCP pathway.
Keywords: Planar cell polarity, Migration, B lymphocyte, VANGL2, Casein kinase 1, MEC1Background
Cell polarization is a prerequisite for the control of cell
shape, directional migration, asymmetric cell division,
and cellular orientation in complex tissues. The WNT/
planar-cell-polarity (PCP) pathway is crucial for the
control of cell polarity. PCP pathway-mediated regula-
tion of cell shape, directional migration, asymmetric cell* Correspondence: gunnar.schulte@ki.se; bryja@sci.muni.cz
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unless otherwise stated.division, and cellular orientation is required for normal
development and function of complex tissues. Although
evolutionary conserved core components of the PCP
pathway and their functions were first identified in in-
vertebrates and in lower vertebrates, the pathway plays
comparably important roles also in human development
[1,2]. Of particular interest, WNT/PCP has been impli-
cated in many human diseases with the most distinguished
positive role in the metastatic process, which accounts for
more than 90% of cancer related deaths [3-6].
The function of the mammalian WNT/PCP machinery
is still poorly understood and progress is hampered
mostly by methodological barriers and limitations ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lishment of well-ordered ommatidia in the compound
eye or cells in the wing epithelium in the fruitfly as well
as convergent extension movements in Xenopus laevis
gastrulation serve as important models of PCP signaling,
assessment of PCP signaling in mammals is more diffi-
cult. In general it requires analysis of embryogenesis of
mutant mouse strains where regular arrangement of sen-
sory hair cells in the inner ear and neural tube closure
phenotypes are the most commonly used readouts for
PCP-like signaling in mammals [7,8]. However, cellular
assays for the assessment of PCP signaling, which would
allow a more detailed mechanistic analysis of PCP func-
tion and possibly also high throughput screening for
chemical compounds targeting mammalian PCP sig-
naling, are still missing.
Here we describe a novel mammalian cell culture model
– the B lymphocyte-derived cell line MEC1 - suitable for
analysis of PCP-like signaling on a single cell level. We
employed live cell imaging and developed a novel and
effective readout correlating subcellular localization of
fluorescently-tagged PCP proteins, such as VANGL2, with
MEC1 cell migration and chemotaxis. Importantly, asym-
metric localization of VANGL2 in MEC1 cells is con-
trolled by the same mechanisms as in mouse embryo as
demonstrated by the requirement of casein kinase 1
(CK1)-mediated phosphorylation [9]. Our work advances
the understanding of the PCP pathway beyond the borders
defined by the powerful Drosophila melanogaster system,
whose transferability is limited because of the evolutionary
distance between the insect wing and compound eye to
organs or cells found in mammals. Furthermore, this high
throughput screen-compatible assay offers novel pos-
sibilities for quantitative assessment of mammalian PCP
signaling and for the development of PCP-targeting drugs.
Results and discussion
MEC1 cells – a robust model for in vitro imaging of B cell
chemotaxis
Our group has recently shown that the WNT/PCP
pathway drives the pathogenesis of chronic lymphocytic
leukemia (CLL) [10]. In that study we introduced the
MEC1 cell model derived from transformed B cells of a
CLL patient [11]. MEC1 cells recapitulate CLL behavior
in many aspects and are used as a xenotransplantation
model for CLL [12].
MEC1 B lymphocytes cultivated on human plasma
fibronectin-coated surfaces show the typical polarized
morphology of a migrating cell with clearly defined leading
and trailing edges (Figure 1A). MEC1 cells are capable to
migrate efficiently as visualized by life cell imaging of
MEC1 cells labeled with Cell Tracker™ Red CMTPX (time
lapse image series in Figure 1B, Additional file 1: Movie 1).
As seen in Figure 1B, MEC1 cells, approximately 15–20 μm in size, can move over the distance of their own size
in less than 4 minutes. Importantly, due to their high mo-
tility, movies of migrating MEC1 cells are easily accessible
to the automated computer-based quantification of migra-
tion parameters of individual cells.
Previously, we have described the basic parameters of
MEC1 cell chemotaxis using transwell migration assays.
In order to confirm that the dynamics in MEC1 migra-
tion seen in transwell assays is reproduced in the mi-
croscopy setting that we apply here, we seeded MEC1
cells in several other commercially available cell culture
setups. The main characteristics of the MEC1 cells ob-
served in the transwell model i.e. increased migration
upon CCL19 and blockade of migration upon CK1 in-
hibition [10] were reproduced in all the tested setups.
First, we have observed the effect in sequential treatments
with control medium (30 min) followed with 30 min of
CCL19 and subsequent CK1 inhibition (30 min) while im-
aging MEC1 migration in standard glass-bottom plates
(Figure 1C). Second, we employed 4-compartment plates
for simultaneous imaging of cells under different ex-
perimental conditions. The individual compartments con-
tained control medium, CCL19 and CCL19/CK1 inhibitor
(Figure 1D). Third, combination of the two approaches,
i.e. simultaneous scanning followed by subsequent treat-
ments is also possible as shown by the experiments in
glass bottom cultivation plates with inserted two-chamber
culture-insert from Ibidi (Munich, Germany) (Figure 1E).
Results in Figure 1 show that migration of MEC1 can
be easily studied by live cell imaging. However, these ex-
periments did not allow studying directionality of migra-
tion in the concentration gradient. In order to overcome
this limitation we introduced Dunn chambers in the
subsequent experiments [13], which were originally de-
signed for imaging adherent cells migrating in a gradient
(Figure 2A). The linear concentration gradient forms
within Dunn chambers in approximately 20 min and is
stable for up to 20 hours. The experiment shown in
Figure 2B was performed repeatedly in three basic
setups: (i) no chemokine (CTRL) in both pools (N = 3),
(ii) chemokine CCL19 gradient with either 400 ng/ml
CCL19 in the outer or inner pool to exclude loading ar-
tifacts (N = 5), and (iii) 400 ng/ml CCL19 in the outer
pool plus casein kinase 1 inhibitor PF670462 (Tocris,
50 μM, N = 3). Cytotracker-stained cells were recorded
by confocal live cell imaging in each condition and sub-
sequently their migration properties (30–60 cells in each
condition) were quantified using Bitplane Imaris Soft-
ware 7.4 according to the procedures described in the
M&M section (Figure 2B). Quantitative image analysis
revealed that cells in the gradient of CCL19 migrated
significantly longer distances compared to cells in con-
trol conditions (Figure 2B “Track length”). Furthermore,
detailed analysis of the individual parameters of cell
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Figure 1 Analysis of B lymphocyte (MEC1) cell migration by live cell imaging. (A) A photomicrograph showing strongly polarized migrating
MEC1 cells with the clearly defined leading and trailing edge. Arrows indicate the direction of migration. Size bar = 10 μm. (B) Snapshots of
migrating, cell tracker-stained, MEC1 cells from time-lapse microscopy at approx. time: 0, 5, 10 and 15 min. Individual moving cells are indicated
by the same color-coded arrow in each snapshot. Size bar = 10 μm. (C) MEC1 cells were seeded on glass-bottom plates coated with human
plasma fibronectin. Control condition was captured first, for 30 min. Subsequently, CCL19 chemokine was added to the cells and the same position
was scanned for additional 30 min. Last, cells were inhibited with PF670462 and followed another 30 min. (D) Four-compartment glass bottom plates
were used for parallel tracking the cells (control [1], CCL19-treated [2] and CCL19/CK1 inhibitor-treated [3]). (E) Ibidi chamber for self-insertion was
inserted in a glass-bottom plate, coated with Fibronectin and cell-tracker stained MEC1 cells were seeded. Ibidi chambers allow parallel scanning in
two conditions (control [1a] and CCL19-stimulated [2a] first, captured for 30 min). After that, cells were stimulated with the chemokine [1b] and one
of the pools was inhibited with the CK1 inh I [2b] and scanned for additional 30 min. From the first period, MEC1 migration in control and CCL19-
stimulated wells [1a, 2a] is compared to each other and after that, CCL19 only and CCL19 + CK1 inh [1b, 2b] are compared to each other. At least
50 cells was tracked in each condition. ***, P < 0.001 (Kruskal-Wallis test).
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sult of increased migration speed (Figure 2B “Speed max”)
and straightness of the track (Figure 2B “Displacement
Length” and “Straightness”). In addition, pharmacological
inhibition of CK1 impeded CCL19-induced changes for all
four migration parameters (Figure 2B).
Dunn chambers provide the unique possibility to
analyze directionality of migration. Some of the migration
parameters analyzed in Figure 2B (mainly “displacement
length” or “straightness”) already allow to indirectly assess
whether the directionality of migration is affected. In
order to analyze the issue of directionality directly we
plotted individual cell trajectories with respect to the
source of chemokine (Figure 2C). Deviation of individual
cells from the source of chemokine was plotted using
Oriana software on the circular diagram and assessedstatistically by Rayleigh’s test. As we show in Figure 2D, in
the absence CCL19 cells migrate randomly whereas in
presence of CCL19 gradient they coordinate and move to-
wards the source of chemokine (P < 0.001). Inhibition of
CK1 by D4476 affected not only the length of the trajec-
tory but also its directionality, which is not significantly
different from random migration (Figure 2D).
Thus, live cell imaging analysis of migration confirmed
our observations seen in transwell assays. We demon-
strated that migration of MEC1 cells can be analyzed by
live imaging in several experimental setups, which allow
both simultaneous analysis under several experimental
conditions as well as analysis of consecutive treatments
with several compounds in a time lapse manner. Im-
portantly, the use of Dunn chambers allows performing
delicate analysis of directionality of MEC1 migration. In
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Figure 2 MEC1 are suitable for analysis of directional chemotaxis. (A) Dunn Chamber: the outer pool is filled with medium with/without
chemokine, the inner pool is filled with medium only. Cells are scanned on the bridge between outer and inner pool. (B) Four graphs describe
chemotaxis of MEC1 cells in a Dunn Chamber. Control (CTRL) - no chemokine gradient between two pools (n = 3). CCL19 gradient between inner
and outer pool (n = 5). CK1 inhibition shows a condition with chemokine gradient between the pools in combination with CK1 inhibitor
PF670642 (n = 3). Migration properties of tracked MEC1 cells are defined by Track length (exact distance of cell path), Track Displacement (distance
of shortest path between each cell’s starting and the end point), Maximum Speed (maximum reached speed of each cell during the whole
measurement) and Straightness (absolutely straight path = 1, minimum= 0). Statistical analysis was performed in GraphPad, using the Kruskal-Wallis
test. (***, P < 0.001). (C) The representative example of trajectories of MEC1 cells in Dunn chamber-generated CCL19 gradient. Cells were treated with
control solution (up) or CK1 inhibitor (bottom). The source of chemokine is indicated by a star. White arrows indicated the direction of migration by
connecting the start and end point. (D) The statistical analysis of the directionality of migration was visualized using Oriana software. Individual blue
dots (corresponding to individual cells) are plotted on the circle based on the deviation of their migration direction from the CCL19 source, which is
set as 0° (up). Data were analyzed by the Rayleigh Test for randomness of circular data. Arrow points towards the predominant direction of cell
migration; arrow length indicates statistical significance where only arrows crossing the inner circle (representing p = 0.05) are statistically significant.
Please note that CCL19 adds a strong directional component to the migration, which is lost following CK1 inhibitor treatment. ***, P < 0.001.
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and robust methodology convenient for imaging of mi-
gration and chemotaxis of B lymphocytes.
Migrating MEC1 cells show a polarized distribution of
planar cell polarity proteins
We have shown earlier that migration of MEC1 cells
(and CLL cells in general) depend on the PCP pathway
and that cellular migration can be blocked e.g. by inhi-
bition of CK1 or by downregulation of DVL2 [10]. Acti-
vity of the PCP pathway is reflected by the asymmetric
subcellular distribution of the core PCP proteins [14]. In
order to find out whether this feature is conserved in
PCP-like signaling in B lymphocytes we took advantage
of the novel model established in Figures 1 and 2. Cells
were transiently transfected with various, fluorescently-
tagged constructs encoding components of the PCP
pathway, such as VANGL2, DVL3, ROR2, and β-arrestin.
The most striking subcellular asymmetry in protein dis-
tribution was observed for the PCP protein VANGL2
(Figure 3A, co-transfected with actin-RFP to visualize cel-
lular morphology). VANGL2-EGFP was distinctly enriched
in the trailing edge, although low levels were also tran-
siently observed in other cell regions. Most of VANGL2, a
four transmembrane-spanning protein, was localized to
the membrane and was enriched in the trailing edge (see
3D reconstruction of VANGL2-EGFP localization in
Additional file 2: Movie 2) where it co-localized with
the typical lymphocyte trailing edge marker CD44 [15]
(Figure 3B). Enrichment in the trailing edge was observed
also for the mCherry-tagged, single transmembrane-
spanning WNT receptor ROR2 (Figure 3C). In contrast,
two other, cytosolic proteins previously implicated in the
PCP pathway – Dishevelled 3 (DVL3) and β-arrestin2
[16-18] – localized predominantly to the leading edge of
the cell (Figure 3D and E). The level of asymmetry can be
quantified by signal intensity measurements (schematized
in Figure 3F) and the quantitative results for individual
PCP proteins are presented in Figure 3G.PCP proteins act as the determinants of cell polarity. As
a next step we thus wanted to exclude the possibility that
the polarized distribution of VANGL2 is simply a conse-
quence of reorganization of actin cytoskeleton, which is
dependent on the polarized cell morphology. We treated
cells with the inhibitors of actin polymerization - cytocha-
lasin D and cytochalasin B – and tested their effects on
VANGL2 polarization. As we show in Figure 3H, and
Additional file 3: Movie 3, destruction of the actin cytoske-
leton by cytochalasin D (cyto D) treatment (15–30 min)
leads to a dramatic change in cell shape – cells round up
and stop moving. Interestingly, the VANGL2-EGFP stays
asymmetrically distributed even after prolonged cyto D
and cyto B treatment (3I). This observation demonstrates
that key polarity determinants (such as VANGL2 in our
case) are polarized even in completely round cells with
compromised cytoskeletal functions, suggesting that pola-
rized distribution of VANGL2 is a cause for and not a con-
sequence of asymmetric shape of a migrating cell.
According to the best of our knowledge this is the first
time that clear polarization of PCP proteins was ob-
served in vitro in cells that are not embedded in tissue
but rather lack cell-cell contact and grow unicellularly. It
has to be mentioned, however, that PCP protein asym-
metry has been recently reported in several cancer cell
types with mesenchymal phenotype [3,19]. Our findings
suggest that PCP proteins in MEC1 cells localize
asymmetrically and recapitulate typical and conserved
features of the core PCP protein localization from Dros-
ophila melanogaster. Strikingly, this is despite the fact
that B lymphocytes lack the persistent cell-cell interac-
tions, which appear to be crucial for cellular asymmetry
in two-dimensional tissues, such as the insect wing or
eye. MEC1 cells can establish PCP-protein polarity
despite the lack of extracellular Flamingo-Flamingo and
Frizzled-VANGL interactions, which provide cell polarity
information from one cell to its neighbor in insect tis-
sues [1]. This raises the question whether the mecha-
nism controlling VANGL2 asymmetry in MEC1 cells is
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Figure 3 Subcellular localization of fluorescently-tagged PCP proteins in polarized MEC1 cells. (A) Photomicrograph of migrating
polarized MEC1 cell with precisely defined leading and trailing edge. VANGL2-EGFP is significantly enriched in the trailing edge of the cell. To
visualize the cytoskeleton, actin-RFP was co-transfected with the VANGL2 construct. Arrow indicates the direction of migration. Size bar = 10 μm.
(B) Co-localization of EGFP-VANGL2 with endogenous CD44, a marker of the trailing edge. (C,D,E) Polarized structure of migrating MEC1 cells
expressing ROR2-mCherry, DVL3-EYFP and β-arrestin 2-EGFP. Arrows indicate the direction of cell migration. Size bars = 10 μm. (F) To quantify the
enrichment of VANGL2-EGFP in the trailing edge, the ratio of the EGFP signal intensity from leading and trailing edge was calculated using
ImageJ software. Size bar = 10 μm. (G) Ratios of the signal intensity in the trailing edge divided by the signal intensity in the leading edge for all
PCP proteins shown in A-E. One dot represents one analyzed cell. Red line indicates ideally symmetric distribution. (H) The effect of Cytochalasin
D treatment on VANGL2-EGFP transfected MEC1 cell is shown after 0, 15 and 30 min. The localization of VANGL2-EGFP does not change even
after the disruption of the actin cytoskeleton. (I) Quantification of individual cells recorded in E. The polarization of VANGL2-EGFP is expressed as
the ratio between the EGFP signal in the trailing edge compared to the leading edge. Cytochalasin B and Cytochalasin D treatment does not
affect the localization of VANGL2-EGFP in the MEC1 cell even though the typical migration morphology has been disrupted by the applied
treatment. (n.s. – not significant).
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lization of VANGL2 in tissues.
Asymmetric localization of VANGL2 in migrating cells is
controlled by casein kinase 1 (CK1)
In order to address this point we have decided to test,
which molecular mechanisms control the asymmetric
localization of PCP proteins in MEC1 cells. We have
chosen the trailing edge-specific localization of VANGL2-
EGFP, which shows the most striking unilateral en-
richment, as the readout. It has been shown earlier that
asymmetric localization of VANGL2 and its function in
mammalian tissues depend on the phosphorylation gra-
dient controlled by CK1 [9]. In line with that we show that
CK1ε can promote, in a CK1-activity dependent manner,
the phosphorylation dependent shift of HA-VANGL2
(Figure 4A). Importantly, inhibition of WNT secretion by
the porcupine inhibitor Wnt-C59 [20] has no effect sug-
gesting that CK1 can bypass eventual requirement for
WNTs. On the other side, co-expression of DVL3, a cru-
cial PCP component, dramatically promotes in synergy
with CK1ε VANGL2 phosphorylation shift in a CK1-
dependent manner (Figure 4A). In order to test whether a
similar mechanism controls the polarized distribution of
VANGL2 in MEC1 cells we have treated VANGL2-EGFP-
expressing MEC1 cells with two chemically unrelated
CK1-specific inhibitors PF670462 (CK1i I) and D4476
(CK1i II). As shown in Figure 4B, the treatment of
CCL19-stimulated MEC1 cells with either of the CK1
inhibitors leads to the clear loss of the posterior accumu-
lation of VANGL2. This effect is quantified by fluores-
cence intensity measurements in Figure 4C.
We hypothesize that asymmetric localization of PCP
proteins correlates with directed migration of MEC1
cells. In order to address this question we treated MEC1
cells with the increasing doses of D4476 and analyzed
the effects on migration index and asymmetric distri-
bution of VANGL2. Even though nonlinear regression of
the dose–response data did not allow exact definition of
EC50 values due to a lack of data points reachingmaximal inhibition at high D4476 concentrations we
aimed at identifying an effective concentration of D4476
close to a halfmaximal effect. Based on the quantifi-
cation of the inhibition of cell migration (Figure 4D) we
obtained substantial but not maximal inhibition at
35 μM D4476 (marked in red). When quantifying
VANGL2 polarization (Figure 4E) in response to in-
creasing concentrations of D4476, 35 μM show a distinct
effect which was not further accentuated by higher
concentration (50 μM). This concentration range is in
agreement with the original data describing the effects
of D4476 on the CK1-mediated phosphorylation in cells
[9,21,22]. Interestingly, mutation of VANGL2 N-terminal
residues previously reported to be phosphorylated by
CK1 – namely S5, S8, S11, S82 and S84 - to alanine
(S5,8,11,82,84A) was not sufficient to disrupt its asym-
metric localization in the trailing edge (Figure 4F). This
suggests that other substrates of CK1 cooperate with
VANGL2 and support its asymmetric distribution. DVL3
(see Figure 4A) and ROR2 [9], which both promote full
VANGL2 phosphorylation and are well-defined CK1 tar-
gets and PCP proteins [23,24], are good candidates serving
this function.
There is an ongoing debate in the field about the role of
WNTs in the asymmetric localization of PCP proteins. In
order to test if autocrine WNT signals could be required
for maintenance of asymmetric localization of VANGL2
in our system we treated MEC1 cells with two porcupine
inhibitors, LGK-974 [25] and Wnt-C59 [20] preventing
WNT secretion, and with soluble Frizzled-related protein
1 (sFRP1) sequestering secreted WNTs. The inhibitors
were used at concentrations that were previously des-
cribed as effective [20,25,26]. Data presented in Figure 4G
show that neither way of inhibiting autocrine WNT sig-
naling disrupts the asymmetric localization of VANGL2.
As the last validation step of our model we wanted to
analyze the role of VANGL2 in the migration of MEC1
cells. We generated a stable MEC1 cell line with Venus-
VANGL2 and Venus-only expression as control. Com-
parison of migratory properties of these cell lines in
Figure 4 (See legend on next page.)
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Figure 4 Pharmacological inhibition of CK1 disturbs VANGL2-EGFP polarization. (A) The effect of CK1ε, DVL3, CK1 inhibitor and Wnt-C59
(porcupine inhibitor) on the electrophoretic mobility of HA-VANGL2 as determined by Western blotting. (B) Snapshots from time-lapse microscopy of
MEC1 cells co-transfected with VANGL2-EGFP and Actin-RFP. All conditions are CCL19-stimulated. Cells were treated with two casein kinase 1 inhibitors:
PF670462 (CK1i-I) and D4476 (CK1i-II). (C) Ratios of the EGFP signal intensity in the trailing edge divided by the EGFP signal intensity in the leading
edge for all three conditions are represented in the bar graph. Statistical analysis was performed using one-way ANOVA and Kruskal-Wallis test in
GraphPad (***, P < 0.001). (D,E) Dose-dependent effects of D4476 (CK1i-II) on MEC1 cell migration, viability and VANGL2 asymmetry are summarized
graphically. Migration (migration index) and asymmetry (ratio of fluorescent intensity in trailing/leading edge) were analysed by nonlinear regression.
35 μM D4476 is labelled red. Data points of viability experiments are shown with a connecting line (no regression). (F,G) Asymmetric distribution of
VANLG2 in MEC1 cells is disturbed neither by the mutation of VANGL2 serines phosphorylated by CK1 to alanine (VANGL2-S5,8,11,82,84A) nor by
inhibition of WNT production by porcupine inhibitors Wnt-C59 (10 μM) and LGK-974 (10 μM) nor by inhibition of WNTs by sFRP1 (10 μg/ml). The
Western blot in F demonstrates that overexpression of CK1/DVL3 is unable to trigger phosphorylation-dependent shift of VANGL2-S5,8,11,82,84A.
(H) Transwell migration assay experiment (N = 3) shows that VANGL2-Venus MEC1 cells respond significantly better to CCL19 stimuli. Number of
migrated cells in 20 μL of sample is shown. Western blot confirms VANGL2-Venus in the stable cell line. (I) MEC1 cells nucleofected by VANGL2 siRNA
show decrease in migration in conditions with and without CCL19. Expression of VANGL2 was significantly decreased 36 h after transfection as
determined by qPCR. Migration in CCL19-treated conditions (H,I) was compared by unpaired t-test (*, P < 0.05).
Kaucká et al. Cell Communication and Signaling  (2015) 13:2 Page 9 of 14transwell assays (Figure 4H) shows that Venus-VANGL2
MEC1 cells respond significantly better to the che-
mokine. In contrast, siRNA-mediated knockdown of
VANGL2 decreased the migratory properties of MEC1
cells (Figure 4I). These data demonstrate that VANGL2
is an important part of the chemotactic machinery that
is both required for efficient migration and capable to
promote chemotaxis when overexpressed.
We conclude that CK1-driven phosphorylation is
required for posterior localization of VANGL2, which
further correlates with the ability of MEC1 cells to di-
rectionally migrate towards the source of chemokine. As
a consequence, we propose that parallel analysis of
VANGL2-asymmetric localization (microscope) and che-
motactic properties (transwell assay) can serve as a
useful approach to discover novel regulators of PCP
signaling.
Based on our findings we propose that microscopic
analysis of the asymmetric distribution of VANGL2-
EGFP is a robust and specific readout for the analysis of
the PCP pathway. This analysis can be combined with
the analysis of migratory properties of MEC1 cells al-
though our results with the actin cytoskeleton blockers
suggest that migration per se does not represent an ideal
readout and can lead to false negative hits. Thus, we
propose that the analysis of VANGL2-asymmetric loca-
lization using a microscope setup can serve as a useful
approach to screen for novel small molecule compounds
targeting mammalian PCP signaling. On the other hands
the relative resistance of MEC1 cells to efficient transfec-
tion with siRNA (not shown) renders them less useful
for siRNA screens, a limitation that might be overcome
in foreseeable time by new developments in gene editing
technologies.
PCP has been described and is still largely studied in
the polarized epithelium in the insect wing or compound
eye. This is mainly due to the combination of powerful
fly genetics and relatively simple scoring of the pheno-
types in fruitfly wings and eyes. The lack of asymmetry,determined either as the loss of asymmetric subcellular
localization of PCP proteins or as the consequent defect
in the positioning of wing bristles and/or individual
ommatidia, has been shown to be a powerful tool for
studying the PCP pathway in Drosophila melanogaster
[27]. So far, a similar tool in mammalian cell culture
systems has been unavailable. This is despite the as-
sumption that the function of the core PCP module in
vertebrates may differ from the mechanisms acting in
the Drosophila melanogaster epithelium. Key PCP pro-
teins are proposed to control mammalian cell shape
changes (e.g. axon guidance), the positioning of basal
bodies, primary cilium formation and asymmetric cell di-
vision (for recent review see [2]). This diversity and com-
plexity implies that various accessory proteins “joined” the
PCP pathway in mammals during evolution and that also
core PCP protein modules might have been reorganized
and modified for the sake of functional divergence and
complex regulation in specialized cell types. Thus, experi-
mental information gained in Drosophila melanogaster
cannot necessarily be extrapolated to the mammalian con-
cept of PCP-like communication.
The MEC1 model system described in this study, how-
ever, has the potential to bridge that gap and to contri-
bute to the current toolboxes for the analysis of PCP
(or PCP-related) pathways and processes in specialized
mammalian cells. Our initial analysis suggests that the
situation in MEC1 cells resembles in many aspects the
core PCP features as established in Drosophila melano-
gaster. Similarly to most other experimental systems (for
recent review see [2,28]) VANGL2 is localized on the
opposite site of the cell than DVL, which suggests a high
level of conservation of the basic PCP features. Our data
also suggest that VANGL2 asymmetry cannot be dis-
rupted by abolishing autocrine WNT signaling. However,
we currently cannot exclude that WNTs are required for
the establishment of the PCP protein asymmetry or that
even low levels of WNTs present despite the use of porcu-
pine inhibitors or sFRP1 are sufficient for maintenance of
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that porcupine blockers can reduce MEC1 migration [10]
but mechanistically it is not clear how. In vertebrate cells
WNTs have been shown to be required for asymmetric
localization of PCP proteins in many contexts including
cells undergoing convergent extension [29,30], elongating
muscle fibers [31] or melanoma cells [19]. Recent work
implicated an instructive role of Wg and dWnt4 in PCP
establishment in Drosophila and proposed a molecular
mechanism how a WNT gradient [32] translates into the
asymmetry of PCP proteins. The authors suggest that
WNTs modulate the intercellular interaction of dFz and
dVang in two neighboring cells, which is a mechanism
that cannot apply to the single cell MEC1 system de-
scribed in this study. We believe that further detailed ana-
lysis of the MEC1 experimental system will help to clarify
the as yet still elusive role of WNTs in PCP [33] especially
in the situation where cells are not embedded in an epi-
thelial sheet.
Conclusions
In summary, our work introduces a novel system for the
analysis of asymmetric distribution of PCP proteins in
relationship to PCP-dependent migration and chemo-
taxis. MEC1 cells may represent a desired model for the
study of polarized distribution (and activity) of the
WNT/PCP pathway in mammalian cell culture. Since
MEC1 cells are migrating cancer cells, whose migration
depends on WNT/PCP signaling [10] with strong po-
larization of VANGL2-EGFP, this model has the capacity
to serve as a novel and long awaited high throughput
screening platform. Adaptation of migration, chemotaxis
and protein localization assays to multiwell plate format
will allow for high throughput screening to identify com-
pounds interfering with mammalian WNT/PCP sig-
naling and for the study of key factors controlling the
polarized distribution of PCP proteins and the activity of
the PCP pathway as such. We believe that our novel
model system has the potential to become the first assay,
which allows unbiased analysis of PCP regulators/inhibi-
tors in a cell culture assay. Compounds/genes identified
in this essay can become a basis for novel therapeutics
targeting PCP pathway in cancer and in metastatic
process.
Methods
Culture and transfection of MEC1 cells
MEC1 cells were obtained from German Collection of
Microorganisms and Cell Cultures (DSMZ). MEC1 were
cultured in suspension in RPMI 1640 supplemented with
10% FBS and antibiotics at 37°C and 5% CO2. Transfec-
tion was performed using Amaxa™ 4D-Nucleofector™ sys-
tem and P3 Primary Cell 4D-Nucleofector® X Kit and the
EO-117 program according to manufacturer’s instructions.Each transfection reaction was performed with 1 × 106 of
MEC1 cells and 5 μg of DNA. After transfection 1 ml of
pre-warmed medium was added into the nucleofection
cuvette and cell were kept for 30 min at 37°C and 5% CO2
and only then transferred to the pre-warmed medium in
T25 flasks. Transfected cells rested overnight before each
experiment. For cell tracking, MEC1 cells were incubated
for 1 hour at 37°C and 5% CO2 with CellTracker™ Red
CMTPX at a final working concentration of 2.5 μM in
serum-free RPMI medium. Subsequently, cells were cen-
trifuged, washed with supplemented RPMI and used for
live cell imaging.
Nucleofection of siRNA to MEC1 cells was performed
by Neon transfection system (Life Technologies) accor-
ding to the user’s manual. 106 cells were transfected by
200nM CTR (Santa Cruz Biotechnology, sc-37007 ) or
specific VANGL2 siRNA (Santa Cruz Biotechnology,
sc-45595) in 10 μL reaction using buffer T. Cells were
co-transfected by 0.5 ug of pmax-GFP per reaction to
control transfection efficiency. After transfection, cells
were incubated at least 24 h in full RPMI medium with-
out antibiotics, then they were harvested for qPCR ana-
lysis of VANGL2 expression or seeded on transwell plate
as described in following sections.Lentivirus production and transductions
Lentiviral particules were produced using 293 T cells by
polyethylenimine transfection of 3 μg VSV-G, 4 μg
psPAX2 and 4 μg of either lenti-puro-VENUS or lenti-
puro-VENUS-VANGL2 in 30-40% confluent monolayer
cell culture grown in 10-cm Petri dishes. Media was
changed 24 hours after transfection and new media was
collected 24 hours later and filtered with syringe filter
0.22 μM. MEC1 cells were transduced in the presence of
10 μg/ml polybrene (Sigma-Aldrich). 24 hours after in-
fection the viral media was replaced by fresh media.
Transduced MEC1 cells were selected using puromycin
(2 μg/mL) over a period of 8 days.Chemical inhibitors and plasmids
Casein kinase 1 inhibitor D4476 (4-[4-(2,3-Dihydro-
1,4-benzodioxin-6-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]
benzamide); casein kinase 1 inhibitor PF670462 (4-[1-
Cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-2-pyrimidi-
namine dihydrochloride); cytochalasin A (7(S)-hydroxy-16
(R)-methyl-10-phenyl-24-oxa[14]cytochalasa-6(12),13
(E),21(E)-triene-1,20,23-trione); cytochalasin D ((7S,13E,
16S,18R,19E,21R)-21-(acetyloxy)-7,18-dihydroxy-16,18-di-
methyl-10-phenyl[11]cytochalasa-6(12),13,19-triene-1,17-dione);
porcupine inhibitor Wnt-C59 (4-(2-Methyl-4-pyridinyl)-
N-[4-(3-pyridinyl)phenyl]benzeneacetamide), porcupine
inhibitor LGK974 (2-(2',3-dimethyl-[2,4'-bipyridin]-5-
yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide).
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ously or commercially available: hVangl2-EGFP [34],
xROR2-mCherry [35], β-arrestin-EGFP [36], mVangl2-HA
[37], xCK1ε [38], hDvl3-flag [39], pDsRed-Monomer-Actin
(Clontech), pmaxGFP (Lonza). hDvl3-EYFP was prepared
by gateway cloning-mediated addition of EYFP on the
C-terminus of Dvl3. Mutated Vangl2-EGFP was prepared
by site directed mutagenesis of the hVangl2-EGFP vec-
tor (Quick change II XL site-directed mutagenesis kit,
Agilent Technologies) of serins S5, 8, 11, 82 and 84 to
alanins, using following mutagenesis primers: sense
S5A 5'-ATGGACACCGAGGCCCAGTACTCGGG-3',
antisense S5A: 5'-CCCGAGTACTGGGCCTCGGTGT
CCAT-3'; sense S8A-S11A 5'-GAGGCCCAGTACGCG
GGCTATGCCTACAAGTCGG-3´, antisense S8A-S11A
5'-CCGACTTGTAGGCATAGCCCGCGTACTGGGCC
TC-3'; sense S82A-S84A 5'-GGCACCTCAGAGCAGG
CCATCGCCCATGATGACCTCA-3', antisense S82A-S84A
S82A-S84A: 5'-TGAGGTCATCATGGGCGATGGCGTG
CTCTGAGGTGCC-3'. Vector used for MEC1 stable cell
line preparation: cDNA of VANGL2 was amplified by
PCR from the and flanked with Asc1/Not1 and cloned
into lenti-puro-VENUS (Clonetech). All PCR-amplified
region was verified by sequencing.
Western blotting
For analysis of VANGL2 phosphorylation, HEK293 cells
were seeded in density of 100 000 cells per well (24-well
plate) and cultured in full DMEM medium (10% FBS,
1% P/S, 1% L-G; Biotech). Following day, they were
transfected with total amount of 0.3 μg DNA per well
using PEI transfection as described in [40]. After 6 h,
medium was replaced by fresh one containing 20 μM
CK1 inhibitor (PF-670462, Tocris), 10 μM Wnt-C59
(ab-142216, Abcam) or corresponding amount of MQ
water and then the cells were incubated for another
24 h. Then they were lysed by 150 μL of 1% Laemmli
buffer per well, sonicated and heated to 98°C for 2 min.
VANGL2-Venus MEC1 cells were peleted (106 cells per
sample, 200 × g, 5 min, RT), washed by PBS and directly
lysed by 1% Laemmli lysis byffer. Western blot analysis
was done according to standard protocol, loading 25 μg
of protein per sample. Proteins were separated by SDS-
PAGE and transferred onto a PDVF membrane (Biotech),
probed with the following primary antibodies: anti-Vangl2
(2G4, [41]), anti-actin (C-11, Santa Cruz Biotechnology,
sc-1615), anti-flag (Sigma-Aldrich, FlagM2 F1804), anti-
HA (Covance, MMS-101R), anti-CK1epsilon (C-20, Santa
Cruz Biotechnology, sc-6471). The secondary antibodies
were used as follows: Anti-Goat IgG (whole molecule) –
Peroxidase antibody produced in rabbit (Sigma-Aldrich,
A4174), Anti-Mouse IgG – Peroxidase antibody produced
in sheep (Sigma-Aldrich, A6782) and Anti-Rat IgG −
Peroxidase antibody produced in goat (Sigma-Aldrich,A9037). Signal was detected by the Fusion system for
western blotting (Vilber Lourmat), Immobilon Western
Chemiluminescent HRP Substrate (Millipore) was used.
Direct immunocytochemistry
MEC1 cells were nucleofected by Neon transfection sys-
tem (Life Technologies) as described above to express
VANGL2-EGFP construct. After the transfection, cells
were incubated for 24 h in full RMPI medium without
antibiotics, then they were seeded on fibronectin coated
glass coverslips (10 μg/mL fibronectin for 1 h, then
blocked by full RPMI medium for 30 min before seeding
cells) in a 24-well plate using complete RPMI medium.
Cells were left to attach to the surface for 2 h. Then the
unattached cells were removed together with medium.
Coverslip with cells was washed carefully with PBS and
cells were fixed by 4% PFA solution in PBS (15 min,
RT). PFA was removed, cells washed twice with PBS and
then PBTA solution containing conjugated primary
CD44-PE/Cy7 antibody (Life Technologies, A16241) was
added. Cells were incubated ON at +4°C in the dark, fol-
lowing day they were washed twice with PBS and the
coverslip was mounted to glass slide by glycerol-gelatine
(Sigma Aldrich, GG1-15 mL). Co-localisation of CD44-
PE/Cy7 and VANGL2-EGFP signals in plasma membrane
was then analyzed by confocal microscopy (Olympus
FluoView 500).
qPCR
Efficiency of VANGL2 siRNA knock-down in MEC1 cels
was assessed by qPCR analysis of nucleofected samples
at least 36 h after transfection. 106 cells were peleted by
centrifugation (200 × g, RT) and RNA was isolated by
RNeasy extraction kit (Quigen). Reverse transcription
was performed using oligo (dT) primer, dNTP mix and
M-MuLV reverse transcriptase (all Thermo Scientific).
VANGL2 and actin (housekeeping gene as a control) ex-
pression was measured using LightCycler® 480 SYBR
Green I Master and primers described previously [10].
Confocal time lapse microscopy
Images and time series were acquired using a Zeiss
LSM710 inverted laser-scanning microscope with Plan-
Apochromat 20× objective. During time-lapse microscopy,
several positions were captured every 20–40 seconds,
depending on the type of experiment and number of
followed positions.
For quantification of fluorescence intensity in the MEC1
cells, the ImageJ software (NIH, Washington, USA) was
used. Based on our knowledge about the migration struc-
ture of MEC1 cells, we divided each cell into front (leading)
and rear (trailing) part and we measured the intensity of
the green channel in two regions-of-interest (ROI) of the
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signal intensity I as R = Itrailing/Ileading.
Analysis of MEC1 migration
MEC1 cells were stained with CellTracker™ Red CMTPX
(Invitrogen) according to manufacturer’s instructions for
1 hour as described above and washed once using culti-
vation medium. For the analysis of migratory properties
of MEC1 cells in the CCL19 gradient, we used the Dunn
chemotaxis chamber (Hawksley, UK). First of all, the
glass coverslip, provided together with the chamber, was
coated with human plasma fibronectin (10 μg/mL) for
1 hour at RT. Subsequently the coverslip was washed and
incubated for another 30 min with FBS-supplemented
RPMI medium. The CellTracker™ Red CMTPX-stained
MEC1 cells were seeded on the coverslip and incubated
for 45–60 minutes at 37°C and 5% CO2. Afterwards, un-
attached cells were gently washed away with the cultiva-
tion medium and exceeding medium was removed by
slightly inclining the cover-slip and using the paper tissue
to soak up the medium at the edge. The inner pool of the
Dunn chamber (Hawksley, Sussex, UK) was filled with
medium and CCL19 chemokine (400 ng/mL, R&D sys-
tems); the outer pool was filled with medium only. We
have also tested inverted combination in order to avoid
loading affects. In that case, both inner and outer pools
were at the first step filled with medium only and the con-
tent of outer pool has been subsequently replaced by fresh
chemokine-supplemented medium. The results of MEC1
cells migration analysis from both tested loading schemes
were comparable, For experiments with inhibitors CK1 in-
hibitor D4476 (100 μM) or PF670462 (50 μM) was added
to both compartments. The inverted cover-slip was placed
on the chamber and the outer well was refilled with fresh
medium exactly according to manufacturer’s instructions.
For 1 hour experiments, no hot wax mixture was placed
to seal the cover slip. The filled chamber was then placed
into the prewarmed microscope chamber at 5% CO2.
Glass-bottom plate/4-compartment glass-bottom plate/
Ibidi chambers were coated with human plasma fibronectin
and MEC1 cells were stained and seeded as described
above. In 4-compartment chambers, stimulation of MEC1
cells was performed at the beginning of each experiment
and 4 positions were scanned at the same time in total for
30 min. In glass-bottom plates, non-stimulated cells were
captured for 30 min as control. Afterwards, CCL19 chemo-
kine was added and cells were captured for another 30 min.
Subsequently, cells were treated with the CK1 inhibitor PF
670462 and scanned again for 30 min. Ibidi chambers
allowed to capture control sample and CCL19-treated sam-
ple for 30 min two different positions simultaneously.
Afterwards, chemokine was added again to both chambers
and in one of the stimulated chambers the CK1 inhibitor
was added. Both positions were scanned for 30 min.Images were captured on a Zeiss LSM710 confocal
microscope. Data were further analyzed using ImageJ
(NIH) software. Cell-tracking analysis was performed
using the Bitplane Imaris Software 7.4 by tracking the
red signal. In order to avoid analysis of dead or perman-
ently immobilized cells, cells for tracking were selected
manually. For the analysis of migration properties of
tracked cells, we picked 4 parameters: track length, dis-
placement length, maximum speed and straightness.
Track length displays and measures the exact path of a
tracked cell. Displacement length shows the shortest
path between the starting and the end point of a tracked
cell. Furthermore, Bitplane Imaris Software provides the
information about maximum speed for each cell and per-
forms specific tracking, which depicts the straightness of
the cell track (ranging from 0 to the maximum 1).Transwell assays
The chemotaxis assay was conducted in HTS Transwell-96
well plates (Corning Incorporated) with 5.0 μm pore size
polycarbonate membranes following the manufacturer’s
instructions.
Total number of 0.3 × 106 MEC1 cells were seeded in the
upper well of the transwell plate. Chemokine gradient was
created by addition of CCL19 chemokine (R&D Systems,
CCL19/MIP-3beta, 361-MI) in concentration of 100 ng/mL
for D4476 dose response testing and 200 ng/mL in case of
VANGL2-Venus or VANGL2 siRNA testing to the lower
well of the plate. Sterile PBS/0.1% BSA solution in corre-
sponding amount was used in control conditions. Cells
were incubated for 6 hours and then number of migrated
cells was analyzed by Accuri C6 Flow Cytometer (BD
Biosciences). The assessment of cell viability was performed
by TMRE staining (Tetramethylrhodamine ethyl ester per-
chlorate, Sigma-Aldrich) as described previously [10]. The
migration index was calculated as the number of cells
(treated or untreated) migrating in response to the chemo-
kine divided by the number of cells migrating toward the
control medium only. Graphs show either migration index
or number of migrated cells in 20 μL of sample taken from
the lower well of the transwell plate.Statistics
Statistical analysis was performed using GraphPad
Prism5 (GraphPad Software Inc., La Jolla, CA, USA).
Nonlinear regression was performed in Graph Pad Prism5
using curve fitting (inhibitory dose response) with variable
slope parameters.
To assess differences in more than two variables, data
were tested by one-way ANOVA and Kruskal-Wallis test
(*, P < 0.05; **, P < 0.01; ***, P < 0.001). Directionality of cell
migration was analyzed using Oriana (Kovach Computing
Services, UK) and Rayleigh’s test.
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Additional file 1: Movie of migrating MEC1 cells. Cell tracker (red)
stained MEC1 cells were observed by confocal microscopy on a
fibroenectin-coated glass surface. Note the distinct polarization of the cells.
Additional file 2: 3D-model of migrating MEC1 cell transfected with
VANGL2-EGFP and actin-RFP. A VANGL2-EGFP and actin-RFP cotransfected
MEC1 cell was imaged employing the Z-stack function of the Zeiss ZEN
software. #D rendering was done with the Imaris 7.6 software. Size bar
10 μm.
Additional file 3: The effect of cytochalasin D treatment on the
distribution of VANGL2-EGFP and the morphology of MEC1 cells. A
living MEC1 cells with distinct polarized VANGL2-EGFP expression on a
fibronectin-coated glass bottom dish was imaged by laser scanning
microscopy. After 22 min the cells were treated with cytochalasin D, a
potent inhibitor of actin polymerization. Note the rapid morphological
changes in MEC1 cells from a polarized migratory phenotype to a
rounded morphology. Simultaneously, the polarized VANGL2-EGFP
distribution is maintained arguing that polarized distribution of VANGL2
is a cause for and not a consequence of asymmetric shape of a
migrating cell.
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